"Quinolones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.
| Descriptor ID |
D015363
|
| MeSH Number(s) |
D03.633.100.810.835
|
| Concept/Terms |
Quinolones- Quinolones
- Quinolinones
- Ketoquinolines
- Oxoquinolines
|
Below are MeSH descriptors whose meaning is more general than "Quinolones".
Below are MeSH descriptors whose meaning is more specific than "Quinolones".
This graph shows the total number of publications written about "Quinolones" by people in this website by year, and whether "Quinolones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 2 | 1 | 3 |
| 2010 | 6 | 0 | 6 |
| 2011 | 4 | 0 | 4 |
| 2012 | 1 | 2 | 3 |
| 2013 | 2 | 2 | 4 |
| 2014 | 2 | 0 | 2 |
| 2017 | 5 | 2 | 7 |
| 2018 | 2 | 0 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 2 | 2 |
| 2025 | 2 | 1 | 3 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinolones" by people in Profiles.
-
Gastrointestinal Burden in Patients With Pancreatic Insufficient Cystic Fibrosis Before and After Elexacaftor/Tezacaftor/Ivacaftor Use. Pancreas. 2025 Nov-Dec 01; 54(10):e858-e862.
-
Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients. J Cyst Fibros. 2021 03; 20(2):333-338.
-
A Dilute and Shoot LC-MS/MS Method for Antipsychotics in Urine. J Anal Toxicol. 2020 May 18; 44(4):331-338.
-
Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor. Pediatrics. 2017 Feb; 139(2).
-
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep; 24(9):2256-61.
-
Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol. 2013 May; 23(4):282-9.
-
Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother. 2012 Apr; 56(4):1680-5.
-
An open-label trial of aripiprazole in the treatment of aggression in male adolescents diagnosed with conduct disorder. Ann Clin Psychiatry. 2011 Nov; 23(4):270-6.
-
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005.
-
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44.